Cyclo Therapeutics Equity Warrants Exp 11 Dec 2025 CYTHW:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
0.16quote price arrow down-0.06 (-27.2727%)
Volume
4
52 week range
0.13 - 0.50
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.22
  • 52 Week High0.50
  • 52 Week High Date06/13/23
  • 52 Week Low0.13
  • 52 Week Low Date01/16/24

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.22
  • 52 Week High0.50
  • 52 Week High Date06/13/23
  • 52 Week Low0.13
  • 52 Week Low Date01/16/24
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cyclo Therapeutics Equity Warrants Exp 11 Dec 2025

 

Profile

MORE
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and...
Markus Sieger
Independent Chairman of the Board
N. Scott Fine
Chief Executive Officer, Director
Jeffrey Tate Ph.D.
Chief Operating Officer, Director
Joshua Fine
Chief Financial Officer, Secretary
Address
6714 Nw 16Th Street,, Suite B
Gainesville, FL
32653
United States